Statins and its Effects on Lipids and Glycemic Status: A Quasi-Experimental Study
DOI:
https://doi.org/10.51253/pafmj.v74i2.8091Keywords:
HMG CoA reductase inhibitors, Statin, Triglycerides, Glycemic StatusAbstract
Objective: To measure changes in lipid and glucose parameters after initiating statin therapy.
Study Design: Quasi-experimental study.
Place and Duration of Study: Department of Pathology and Medicine, Naval Hospital, Islamabad Pakistan, from Nov 2018 to
Oct 2020.
Methodology: Thirty-nine male individuals participated in the study after a detailed explanation and consenting procedure.
At the outset of the study, baseline testing of fasting plasma glucose and lipid parameters was done. Participants were then
started with 10 mg of Atorvastatin/day for six weeks, with visits every two weeks for testing for lipids and glucose.
Results: The mean age of participants was 42.47+11.65 years. %Δ (change) in mean (X) from baseline to result of last reading at
six weeks for various evaluated parameters were as: %ΔX Fasting plasma glucose = +91.45, %ΔX total cholesterol=-139.63,
%ΔX fasting triglycerides=-1.04%ΔX LDLc= -150.49 and %ΔXHDLc= -105.25. For HDLC, 14/31 showed a rise in levels
compared to 17/31, who demonstrated a downward trend after starting statin therapy, indicating a differential response
among subjects taking statin therapy.
Conclusion: Mean glucose levels increased from baseline to six weeks, whereas the mean of all lipid indices (including HDLc)
declined in subjects on statin therapy.
Downloads
References
Endo A. The discovery and development of HMG-CoA
reductase inhibitors. J Lipid Res 1992; 33(11): 1569-1582.
O'Keeffe AG, Nazareth I, Petersen I. Time trends in the
prescription of statins for the primary prevention of
cardiovascular disease in the United Kingdom: a cohort study
using The Health Improvement Network primary care data. Clin
Epidemiol 2016; 8: 123-132.
https://doi.org/10.2147/CLEP.S104258
Cho KI, Sakuma I, Sohn IS, Hayashi T, Shimada K, Koh KK. Best
Treatment Strategies with Statins to Maximize the
Cardiometabolic Benefits. Circ J2018; 82(4): 937-943.
https://doi.org/10.1253/circj.CJ-17-1445
Zhang Y, Liang M, Sun C, Qu G, Shi T, Min M, et al. Statin Use
and Risk of Pancreatic Cancer: An Updated Meta-analysis of 26
Studies. Pancreas 2019; 48(2): 142-150.
https://doi.org/10.1097/MPA.0000000000001226
McTaggart F, Jones P. Effects of statins on high-density
lipoproteins: a potential contribution to cardiovascular benefit.
Cardiovasc Drugs Ther 2008;22(4):321-338.
https://doi.org/10.1007/s10557-008-6113-z
Puri R, Nissen SE, Shao M, Kataoka Y, Uno K, Kapadia SR, et al.
The beneficial effects of raising high-density lipoprotein
cholesterol depends upon achieved levels of low-density
lipoprotein cholesterol during statin therapy: Implications for
coronary atheroma progression and cardiovascular events. Eur J
Prev Cardiol 2016; 23(5): 474-485.
Bergheanu SC, Van Tol A, Dallinga-Thie GM, Liem A,
Dunselman PH, Van der Bom JG, et al. Effect of rosuvastatin
versus atorvastatin treatment on paraoxonase-1 activity in men
with established cardiovascular disease and a low HDLcholesterol. Curr Med Res Opin 2007; 23(9): 2235-2240.
https://doi.org/10.1185/030079907X226104
Catapano AL. Pitavastatin and HDL: Effects on plasma levels
and function(s). Atheroscler Suppl 2017; 27: e1-e9.
https://doi.org/10.1016/j.atherosclerosissup.2017.05.001
Adams SP, Sekhon SS, Tsang M, Wright JM. Fluvastatin for
lowering lipids. Cochrane Database Syst Rev 2018; 3(3):
CD012282.
https://doi.org/10.1002/14651858.CD012282.pub2
Sonal Sekhar M, Unnikrishnan MK. South-Asian population has
a higher likelihood for diabetes risk for statins regardless of
potency. Med Hypotheses 2015; 84(3): 283-284.
https://doi.org/10.1016/j.mehy.2014.12.026
Woo HI, Kim SR, Huh W, Ko JW, Lee SY. Association of genetic
variations with pharmacokinetics and lipid-lowering response to
atorvastatin in healthy Korean subjects. Drug Des Devel Ther
; 11: 1135-1146.
https://doi.org/10.2147/DDDT.S131487
Wang P. Statin dose in Asians: is pharmacogenetics relevant?
Pharmacogenomics 2011; 12(11): 1605-1615.
https://doi.org/10.2217/pgs.11.98
Reiner Z. Managing the residual cardiovascular disease risk
associated with HDL-cholesterol and triglycerides in statintreated patients: a clinical update. Nutr Metab Cardiovasc Dis
; 23(9): 799-807.
https://doi.org/10.1016/j.numecd.2013.05.002
Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert
E, et al. European Atherosclerosis Society Consensus Panel.
Adverse effects of statin therapy: perception vs. the evidence -
focus on glucose homeostasis, cognitive, renal and hepatic
function, haemorrhagic stroke and cataract. Eur Heart J 2018;
(27): 2526-2539.
https://doi.org/10.1093/eurheartj/ehy182
Carmena R, Betteridge DJ. Diabetogenic Action of Statins:
Mechanisms. Curr Atheroscler Rep 2019; 21(6): 23.
https://doi.org/10.1007/s11883-019-0780-z
Laakso M, Kuusisto J. Diabetes Secondary to Treatment with
Statins. Curr Diab Rep 2017; 17(2):1 0.
https://doi.org/10.1007/s11892-017-0837-8
Cederberg H, Stančáková A, Yaluri N, Modi S, Kuusisto J,
Laakso M. Increased risk of diabetes with statin treatment is
associated with impaired insulin sensitivity and insulin
secretion: a 6 year follow-up study of the METSIM cohort.
Diabetologia 2015; 58(5): 1109-1117.
https://doi.org/10.1007/s00125-015-3528-5
Agouridis AP, Kostapanos MS, Elisaf MS. Statins and their
increased risk of inducing diabetes. Expert Opin Drug Saf 2015;
(12): 1835-1844.
https://doi.org/10.1517/14740338.2015.1096343
Rochlani Y, Kattoor AJ, Pothineni NV, Palagiri RDR, Romeo F,
Mehta JL. Balancing Primary Prevention and Statin-Induced
Diabetes Mellitus Prevention. Am J Cardiol 2017; 120(7): 1122-
https://doi.org/10.1016/j.amjcard.2017.06.054
Ambrosy AP, Yang J, Sung SH, Allen AR, Fitzpatrick JK, Rana
JS, et al. Triglyceride Levels and Residual Risk of Atherosclerotic
Cardiovascular Disease Events and Death in Adults Receiving
Statin Therapy for Primary or Secondary Prevention: Insights
From the KP REACH Study. J Am Heart Assoc 2021; 10(20):
e020377. https://doi.org/10.1161/JAHA.120.020377
Hirayama K, Ota T, Harada K, Shibata Y, Tatami Y, Harata S, et
al. Impact of Paradoxical Decrease in High-density Lipoprotein
Cholesterol Levels After Statin Therapy on Major Adverse
Cardiovascular Events in Patients with Stable Angina Pectoris.
Clin Ther 2017; 39(2): 279-287.
Downloads
Published
Issue
Section
How to Cite
